白血病患者伊马替尼药代动力学与CYP3A4活性的关系
该研究纳入19例接受伊马替尼治疗的慢性髓性白血病或急性淋巴细胞白血病患者,评估内源性生物标志物4β-羟基胆固醇与CYP3A4活性的关系及其对伊马替尼药代动力学的影响。结果显示4β-羟基胆固醇/胆固醇比值与伊马替尼清除率显著正相关,可解释30%的变异,支持其作为CYP3A4活性标志物用于个体化给药。
要点
- 4β-羟基胆固醇/胆固醇比值与伊马替尼清除率显著正相关,解释30%变异。
- CYP3A4活性与N-去甲基伊马替尼AUC/伊马替尼AUC比值无显著关联。
- 给药后3-4小时单点采样的伊马替尼浓度与AUC0-24h相关性优于谷浓度。
核心结论
- 4β-羟基胆固醇/胆固醇比值与伊马替尼清除率显著正相关,可解释30%的变异。
- CYP3A4活性与N-去甲基伊马替尼AUC/伊马替尼AUC比值无显著关联。
- 本研究首次在伊马替尼治疗的白血病患者中探讨4β-羟基胆固醇作为CYP3A4活性标志物,支持进一步开发该个体化治疗策略。
研究设计与样本
- 药代动力学研究纳入19例接受伊马替尼治疗的慢性髓性白血病或急性淋巴细胞白血病患者。
- 采集24小时血样,用LC-MS/MS测定伊马替尼、N-去甲基伊马替尼、4β-羟基胆固醇和4α-羟基胆固醇血浆浓度。
- 用临床化学自动分析仪测定总胆固醇,以4β-羟基胆固醇/胆固醇比值估计CYP3A4活性。
- 对相关CYP3A4/5基因变异进行基因分型,用PKanalix软件估算药代动力学参数,并进行简单和多元线性回归。
主要发现
- 19例患者中位年龄66岁(范围44-77)。
- 药代动力学参数与既往报道相当。
- 4β-羟基胆固醇/胆固醇比值与伊马替尼清除率显著正相关,解释30%的变异。
- CYP3A4活性与N-去甲基伊马替尼AUC/伊马替尼AUC比值无显著关联。
- 给药后3-4小时单点采样的伊马替尼浓度与AUC0-24h相关性优于谷浓度。
临床怎么用
- 4β-羟基胆固醇/胆固醇比值有望作为CYP3A4活性标志物,用于伊马替尼的主动剂量优化。
- 给药后3-4小时单点采样可作为伊马替尼AUC0-24h的替代指标,优于谷浓度。
局限性
- CYP3A4/5基因型评估受患者数量少限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity-the main imatinib-metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady-state conditions and frequent sampling. The endogenous biomarker 4β-hydroxycholesterol (4-β-OHC) has been proposed to reflect CYP3A4 activity, enabling proactive dose optimization. This study investigated 4-β-OHC as a CYP3A4 biomarker in leukaemia patients and its relationship with imatinib pharmacokinetics METHODS: A pharmacokinetic study included 19 patients with chronic myeloid leukaemia or acute lymphoblastic leukaemia receiving imatinib. Blood samples were collected over 24 h. Imatinib, N-desmethyl imatinib, 4-β-OHC and 4α-hydroxycholesterol (4-α-OHC) plasma concentrations were quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS), while total cholesterol was measured by clinical chemistry autoanalyser. CYP3A4 activity was estimated using the 4-β-OHC/cholesterol ratio. Genotyping of relevant CYP3A4/5 gene variants was carried out. Pharmacokinetic parameters were estimated using PKanalix software. Simple and multiple linear regressions were performed RESULTS: Nineteen patients were included with median age of 66 years (range 44-77). Pharmacokinetic parameters were comparable to prior reporting. The 4-β-OHC/cholesterol ratio showed a significant positive association with imatinib clearance, explaining 30% of variance. No significant association was found between CYP3A4 activity and N-desmethyl-imatinib area under the concentration time-curve (AUC)/imatinib AUC ratio. Single-point sampling of imatinib at 3-4 h post-dose correlated better with AUC0 -24h than trough concentrations. CYP3A4/5 genotype assessment was limited by low patient numbers CONCLUSION: This is the first study investigating 4-β-OHC as a biomarker for CYP3A4 activity in imatinib-treated leukaemia patients, demonstrating clinically meaningful associations with imatinib clearance and supporting further development of this personalized therapy approach.
引用
- Rasmussen ASB, Koch MR, Rank CU, et al. Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients. Br J Clin Pharmacol. 2026. PMID: 42208992. doi:10.1002/bcp.70622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。